ImmuPharma (LON:IMM) Shares Down 8.5% – What’s Next?
by Renee Jackson · The Cerbat GemImmuPharma plc (LON:IMM – Get Free Report) shares traded down 8.5% during mid-day trading on Monday . The stock traded as low as GBX 4.40 and last traded at GBX 4.40. 1,523,292 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 2,874,877 shares. The stock had previously closed at GBX 4.81.
ImmuPharma Price Performance
The stock has a market capitalization of £27.45 million, a price-to-earnings ratio of -11.89 and a beta of 2.98. The firm’s fifty day moving average is GBX 4.48 and its 200-day moving average is GBX 5.83.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. On average, sell-side analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.